Biogen
Sage Therapeutics Files Lawsuit Against Biogen Following $469 Million Acquisition Offer
Sage Therapeutics, Biogen, lawsuit, acquisition offer, $469 million, neuroscience, pharmaceutical industry
Alzheimer’s Market Set for Eightfold Boom: Lilly, Eisai, and Biogen Lead the Charge
Alzheimer’s disease market, Eli Lilly, Eisai, Biogen, Market growth, Donanemab (Kisunla), Leqembi
Biogen Proposes Acquisition of Sage Therapeutics in $442 Million Deal
Biogen, Sage Therapeutics, acquisition, neuro biotech, zuranolone, postpartum depression, major depressive disorder
Eisai Slashes Leqembi Sales Forecast Amid Continued Launch Challenges
Eisai, Leqembi, Alzheimer’s disease, sales forecast, revenue expectations, Biogen, pharmaceutical industry
Biogen Raises Profit Guidance Amid Leqembi Growth and MS Sales Decline
Biogen, profit guidance, Leqembi, multiple sclerosis, earnings report, pharmaceutical industry
Leqembi’s Global Sales Reach $67 Million, Yet US Adoption Faces Hurdles
Leqembi, Biogen, Eisai, Alzheimer’s disease, global sales, US adoption challenges
Biogen Expands Portfolio with Neomorph Molecular Glues Deal Worth Up to $1.45 Billion
Biogen, Neomorph, Molecular Glues, Biotech Deal, Pharmaceutical Acquisition
Biogen and Sage Discontinue Plans for Major Depressive Disorder Approval for Zurzuvae
Biogen, Sage Therapeutics, Zurzuvae, postpartum depression, major depressive disorder, FDA approval
Eisai to Seek Reconsideration of TGA’s Initial Decision on Lecanemab for Alzheimer’s Disease in Australia
Lecanemab, Alzheimer’s disease, Therapeutic Goods Administration (TGA), Eisai, Biogen, reconsideration, Australia
Biogen’s Higher Dose Spinraza Shows Enhanced Efficacy in Treating Spinal Muscular Atrophy
Biogen, Spinraza, Nusinersen, Spinal Muscular Atrophy (SMA), Higher Dose Regimen, Clinical Trial Results, DEVOTE Study, Motor Function Improvement, Neurodegeneration Reduction